Tirzepatide and Semaglutide: Understanding the Difference
Important information. Compounded semaglutide and compounded tirzepatide are not FDA-approved products. The FDA has not evaluated compounded versions of these medications for safety, effectiveness, or quality. Both are prescription medications that require evaluation by a licensed provider and are not appropriate for everyone. This article is general educational information, not medical advice, and is not an offer to sell prescription medication.
Two medications, two mechanisms
Semaglutide and tirzepatide are prescription medications studied for blood sugar control and, in certain FDA-approved products, chronic weight management. They are frequently discussed together, but they do not work in identical ways.
Semaglutide
Semaglutide is a GLP-1 receptor agonist. It acts on receptors for glucagon-like peptide-1, a hormone the body releases after eating that helps regulate blood sugar, slows stomach emptying, and signals fullness to the brain.
Tirzepatide
Tirzepatide acts on two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism is the primary pharmacological difference between the two medications.
What the research shows
In clinical trials of the FDA-approved products containing these ingredients, both produced meaningful average weight reduction when combined with reduced-calorie eating and increased physical activity. Trials of approved tirzepatide products have reported larger average reductions than trials of approved semaglutide products, though the studies differ in design and population, and individual responses vary widely.
All of this research was conducted on FDA-approved products. Compounded preparations of either ingredient have not been studied in comparable trials, and these findings should not be assumed to apply to them. Individual results vary and no outcome is guaranteed.
Branded and compounded preparations are not the same thing
FDA-approved branded products come first. Where an FDA-approved product is appropriate for you, that is what your provider will prescribe. Prescriptions are sent to the manufacturer's direct pharmacy service or to your own pharmacy, depending on the medication and your coverage. These products have been evaluated by the FDA for safety, effectiveness, and manufacturing quality.
Compounded preparations are an individualized alternative, not a substitute. A compounded medication is prepared for a specific patient by a compounding pharmacy and is not FDA-approved. It is appropriate only where a documented clinical need makes the commercially available product unsuitable for that particular patient. Cost or convenience alone is not a clinical basis for compounding.
Your provider will tell you which category any prescription falls into and the reasoning behind it. If you are ever unsure whether a medication you have been prescribed is an FDA-approved product or a compounded preparation, ask.
Side effects and risks
Both medications share a similar side effect profile: nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite are the most commonly reported, and are often most noticeable early in treatment.
Serious risks reported with the FDA-approved products in this class include pancreatitis, gallbladder disease, kidney injury related to dehydration, and low blood sugar when combined with insulin or a sulfonylurea. FDA-approved semaglutide and tirzepatide products carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies; whether this risk applies to humans has not been determined.
Neither medication is appropriate for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2; people who are pregnant, trying to become pregnant, or breastfeeding; people with a history of pancreatitis; or people with certain other medical conditions.
Dosing
Both are administered as weekly injections and both follow a gradual step-up schedule, beginning at a low dose and increasing over time under provider supervision to reduce the intensity of side effects.
Which is appropriate for a given patient?
That determination belongs to a licensed provider who has reviewed your complete health history, current medications, and treatment goals. There is no universally correct answer between these two medications, and some patients are appropriate candidates for neither.
How care works at Slender Me Medical
Slender Me Medical is LegitScript certified, and prescriptions are fulfilled through a LegitScript-certified pharmacy. We do not sell prescription medication directly to consumers. Care begins with a clinical evaluation with our licensed nurse practitioner, available by telehealth to patients located in states where our provider holds an active license, or in person at our Corona, CA office. Your provider will review options, risks, benefits, alternatives, and cost with you before anything is prescribed. A consultation does not guarantee that any medication will be prescribed.
Call (951) 898-8515 to request a consultation.
This article is provided for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It does not create a provider-patient relationship. Always consult a qualified healthcare professional about your individual circumstances. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality.